-+ 0.00%
-+ 0.00%
-+ 0.00%

SENTI BIO’S SENTI-202, A FIRST-IN-CLASS OFF-THE-SHELF LOGIC GATED SELECTIVE CD33 OR FLT3 NOT EMCN CAR NK CELL THERAPY, DEMONSTRATES POSITIVE PRELIMINARY CLINICAL RESULTS IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AML

Reuters·04/28/2025 11:00:01

Please log in to view news